RecruitingNot ApplicableNCT04899102

Intermittent Fasting for NAFLD in Adults

Pilot Study of Time-Restricted, Intermittent Fasting for Non-Alcoholic Fatty Liver Disease in Non-Obese Adults

Sponsor

Massachusetts General Hospital

Enrollment

25 participants

Start Date

Feb 1, 2022

Study Type

INTERVENTIONAL

Conditions

Non-Alcoholic Fatty Liver Disease Fatty Liver Liver Fat Fatty Liver, Nonalcoholic Intermittent Fasting

Summary

NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI\<30kg/m2) is an increasingly recognized condition, sometimes described as "lean NAFLD". Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. The purpose of this study is to identify non-pharmacologic, lifestyle-based methods of NAFLD treatment within non-obese adults.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether time-restricted intermittent fasting — limiting eating to a specific window of hours during the day — can reduce liver fat in adults with non-alcoholic fatty liver disease (NAFLD) who are not obese, a group sometimes called "lean NAFLD." Since there are no FDA-approved drug treatments for NAFLD, finding effective lifestyle approaches for this specific group is an important goal. Adults aged 18 or older with a BMI between 23 and 30 kg/m², confirmed liver fat of at least 10% on MRI, and no heavy alcohol use or other liver diseases may be eligible. Participation involves following an intermittent fasting eating schedule and attending clinic visits over several months for liver fat measurements via MRI, blood tests, and assessments of metabolic health. This summary was generated by AI to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.